Friday 21 March 2014

PROSENSA RELEASE 48 WEEK DATA FROM DRISAPERSEN STUDY

Prosensa today released 48-week drisapersen data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V).

The results of this study indicate that, compared to placebo, some boys in the higher-dose drisapersen group (6 mg/kg once weekly) reported improvements in their muscle function and physical activity as measured by the six-minute walk test (6MWT) for the 24-week treatment phase and maintained this improvement during the 24-week follow-up period.

No comments:

Post a Comment